Evidence map›Paper›PMID 37050415›Full record

ReviewPolymers2023

Microbial Exopolysaccharide Composites in Biomedicine and Healthcare: Trends and Advances.

Vishal Ahuja, Arvind Kumar Bhatt, J Rajesh Banu, Vinod Kumar, Gopalakrishnan Kumar, Yung-Hun Yang, Shashi Kant Bhatia

Abstract readReview
In one paragraph

Review in Polymers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Engineering Microbial Particles for Next-Generation Biomedical Platforms.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Levan Production byMolecules (Basel, Switzerland) · 2024
    Article
  17. Article
  18. Review
  19. Review
  20. Production of Bacterial Exopolysaccharides: Xanthan and Bacterial Cellulose.International journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Vishal AhujaUniversity Institute of Biotechnology, Chandigarh University, Mohali 140413, Punjab, India.ORCID 0000-0001-8982-4978
Arvind Kumar BhattDepartment of Biotechnology, Himachal Pradesh University, Shimla 171005, Himachal Pradesh, India.ORCID 0000-0003-0825-6783
J Rajesh BanuDepartment of Life Sciences, Central University of Tamil Nadu, Thiruvarur 610005, Tamil Nadu, India.ORCID 0000-0001-7708-452X
Vinod KumarCentre for Climate and Environmental Protection, School of Water, Energy and Environment, Cranfield University, Cranfield MK43 0AL, UK.
Gopalakrishnan KumarInstitute of Chemistry, Bioscience and Environmental Engineering, Faculty of Science and Technology, University of Stavanger, P.O. Box 8600 Forus, 4036 Stavanger, Norway.ORCID 0000-0002-7848-5138
Yung-Hun YangDepartment of Biological Engineering, College of Engineering, Konkuk University, Seoul 05029, Republic of Korea.
Shashi Kant BhatiaDepartment of Biological Engineering, College of Engineering, Konkuk University, Seoul 05029, Republic of Korea.ORCID 0000-0002-7688-6069

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Microbial exopolysaccharides (EPSs), e.g., xanthan, dextran, gellan, curdlan, etc., have significant applications in several industries (pharma, food, textiles, petroleum, etc.) due to their biocompatibility, nontoxicity, and functional characteristics. However, biodegradability, poor cell adhesion, mineralization, and lower enzyme activity are some other factors that might hinder commercial applications in healthcare practices. Some EPSs lack biological activities that make them prone to degradation in ex vivo, as well as in vivo environments. The blending of EPSs with other natural and synthetic polymers can improve the structural, functional, and physiological characteristics, and make the composites suitable for a diverse range of applications. In comparison to EPS, composites have more mechanical strength, porosity, and stress-bearing capacity, along with a higher cell adhesion rate, and mineralization that is required for tissue engineering. Composites have a better possibility for biomedical and healthcare applications and are used for 2D and 3D scaffold fabrication, drug carrying and delivery, wound healing, tissue regeneration, and engineering. However, the commercialization of these products still needs in-depth research, considering commercial aspects such as stability within ex vivo and in vivo environments, the presence of biological fluids and enzymes, degradation profile, and interaction within living systems. The opportunities and potential applications are diverse, but more elaborative research is needed to address the challenges. In the current article, efforts have been made to summarize the recent advancements in applications of exopolysaccharide composites with natural and synthetic components, with special consideration of pharma and healthcare applications.

Indexed as

biopolymersEPS compositesexopolysaccharidesfoodhealthcare

Identifiers

PMID37050415
PMCPMC10098801

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.